Found: 8
Select item for more details and to access through your institution.
A multidimensional assessment of the burden of psoriasis: results from a multinational dermatologist and patient survey.
- Published in:
- British Journal of Dermatology, 2018, v. 179, n. 1, p. 173, doi. 10.1111/bjd.16332
- By:
- Publication type:
- Article
Differential effects of secukinumab vs. ustekinumab for treatment of psoriasis on quality of life, work productivity and activity impairment: a structural equation modelling analysis.
- Published in:
- British Journal of Dermatology, 2018, v. 178, n. 6, p. 1297, doi. 10.1111/bjd.16366
- By:
- Publication type:
- Article
Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study.
- Published in:
- British Journal of Dermatology, 2017, v. 177, n. 4, p. 1033, doi. 10.1111/bjd.15706
- By:
- Publication type:
- Article
Secukinumab significantly reduces psoriasis‐related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom.
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2018, v. 32, n. 12, p. 2178, doi. 10.1111/jdv.15094
- By:
- Publication type:
- Article
Cost‐effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany.
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2018, v. 32, n. 12, p. 2191, doi. 10.1111/jdv.15047
- By:
- Publication type:
- Article
Patient–dermatologist agreement in psoriasis severity, symptoms and satisfaction: results from a real‐world multinational survey.
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2018, v. 32, n. 9, p. 1523, doi. 10.1111/jdv.14937
- By:
- Publication type:
- Article
Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study.
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2017, v. 31, n. 10, p. 1693, doi. 10.1111/jdv.14391
- By:
- Publication type:
- Article
Incremental burden of cardiovascular comorbidity and psoriatic arthritis among adults with moderate-to-severe psoriasis in five European countries.
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2017, v. 31, n. 8, p. 1316, doi. 10.1111/jdv.14286
- By:
- Publication type:
- Article